CureVac: Clinical Trials

2 completed, 2 withdrawn, 1 terminated. 5 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	5	Completed 2, Withdrawn 2, Terminated 1
Phase 2	1	Completed 1

Follow CureVac: new trials by email

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older SARS-CoV-2 mRNA Vaccine (CVnCoV), Quadrivalent influenza vaccine (QIV), Placebo - SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19)	Phase 3	Withdrawn	Bayer		2021-10-01	2021-08-11
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 CVnCoV Vaccine - Coronavirus, Covid19	Phase 3	Withdrawn	CureVac		2021-10-01	2021-08-20
COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities CVnCoV Vaccine - Coronavirus, Covid19	Phase 3	Terminated	CureVac	129	2021-04-22	2022-05-13
A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19 CVnCoV Vaccine, Placebo - Coronavirus, Covid19	Phase 3	Completed	CureVac	2357	2020-12-23	2023-10-06
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older CVnCoV, Placebo, Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program - Covid19, SARS-CoV-2	Phase 2 / Phase 3	Completed	CureVac	39680	2020-12-11	2024-04-29

Conditions studied

COVID-19 (5)  ·  Coronavirus Infections (3)  ·  Severe Acute Respiratory Syndrome (3)

Interventions

CVnCoV COVID-19 vaccine (5)  ·  Influenza Vaccines (1)

Countries

Belgium (2)  ·  Germany (2)  ·  Argentina (1)  ·  Colombia (1)  ·  Dominican Republic (1)  ·  Mexico (1)  ·  Netherlands (1)  ·  Panama (1)  ·  Peru (1)  ·  Spain (1)

Results publications

PMID 34826381, PMID 39040887